Showing results (1821-1830 of 1,922) with videos related to

Sort By:
Pageof 193
The Lancet. Infectious Diseases|November 10, 2021
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort studyAnika Singanayagam, Seran Hakki, Jake Dunning, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 9, 2021
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Setting-specific Transmission Rates: A Systematic Review and Meta-analysisHayley A Thompson, Andria Mousa, Amy Dighe, et al.
Emerging Infectious Diseases|September 12, 2020
Early Insights from Statistical and Mathematical Modeling of Key Epidemiologic Parameters of COVID-19Matthew Biggerstaff, Benjamin J Cowling, Zulma M Cucunubá, et al.
Science (New York, N.Y.)|October 12, 2019
Spatial control of heavy-fermion superconductivity in CeIrIn<sub>5</sub>Maja D Bachmann, G M Ferguson, Florian Theuss, et al.
Wellcome Open Research|December 17, 2021
Estimating the number of undetected COVID-19 cases among travellers from mainland ChinaSangeeta Bhatia, Natsuko Imai, Gina Cuomo-Dannenburg, et al.
Biological Reviews of the Cambridge Philosophical Society|June 20, 2019
A way forward with eco evo devo: an extended theory of resource polymorphism with postglacial fishes as model systemsSkúli Skúlason, Kevin J Parsons, Richard Svanbäck, et al.
Oncoimmunology|February 5, 2019
Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patientsHansol Lee, Camelia Quek, Ines Silva, et al.
Biological Psychiatry|September 11, 2007
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phasesMartin B Keller, Madhukar H Trivedi, Michael E Thase, et al.
Lancet (London, England)|June 5, 2003
Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong KongChristl A Donnelly, Azra C Ghani, Gabriel M Leung, et al.
The Lancet. Oncology|June 8, 2019
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF<sup>V600</sup> mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trialGeorgina V Long, Robyn P M Saw, Serigne Lo, et al.
Pageof 193